Effectiveness of Pentavalent Rotavirus Vaccine Against Severe Disease
Pediatrics, 08/15/2011
Staat MA et al. – Pentavalent rotavirus vaccine (RV5) was highly effective in preventing severe rotavirus disease, even after a partial series, with protection persisting throughout the second year of life.
Methods- Active, prospective population–based surveillance for AGE and acute respiratory infection (ARIs) in inpatient and emergency department settings provided subjects for a case–control evaluation of VE in 3 US counties from January 2006 through June 2009.
- Children with laboratory–confirmed rotavirus AGE (cases) were matched according to date of birth and onset of illness to 2 sets of controls: children with rotavirus–negative AGE and children with ARI.
- The main outcome measure was VE with complete (3 doses) or partial (1 or 2 doses) RV5 vaccination.
- Of age–eligible children enrolled, 18% of cases, 54% of AGE controls, and 54% of ARI controls received >1 dose of RV5.
- The VE of RV5 for 1, 2, and 3 doses against all rotavirus genotypes with the use of rotavirus–negative AGE controls was 74% and 87%, respectively, and with the use of ARI controls was 73%, 88%, and 85%, respectively.
- The overall VE estimates were comparable during the first and second years of life and against AGE caused by different rotavirus strains.